StockWatch
·
Biotechnology: Pharmaceutical Preparations
Clinical TrialNov 17, 2026, 04:40 PM

Alzamend Neuro Pauses BD Trial After FDA Feedback; MGH Terminates SOW

AI Summary

Alzamend Neuro, Inc. has paused its bipolar disorder (BD) clinical trial for AL001 due to challenges with eligibility criteria and FDA feedback. The FDA did not support the proposed modifications and suggested efficacy and safety trials may be more appropriate for an NDA. The company plans to request a Type B meeting with the FDA to discuss a revised development plan, potentially skipping Phase II trials and moving directly to Phase III for BD. Separately, the BD Statement of Work (SOW) with Massachusetts General Hospital (MGH) has been terminated, with MGH reassigning staff. The company will receive a refund of approximately $25,000. The termination does not impact the Master Clinical Trial Agreement or the healthy subjects SOW. Final results for the healthy subjects clinical trial are expected in December 2026.

Key Highlights

  • Alzamend Neuro paused its bipolar disorder (BD) clinical trial for AL001 after FDA feedback indicated proposed eligibility criteria modifications were not supported.
  • The FDA suggested efficacy and safety trials may be more appropriate to support a New Drug Application (NDA) for AL001 in BD.
  • Alzamend plans to request a Type B meeting with the FDA to discuss a revised clinical development plan, potentially moving directly to Phase III trials for BD.
  • Massachusetts General Hospital (MGH) terminated the BD Statement of Work (SOW) due to the trial being paused for an extended period.
  • Alzamend will receive a refund of approximately $25,000 from MGH for unused funds related to the BD SOW.
  • The termination of the BD SOW does not impact the Master Clinical Trial Agreement or the healthy subjects SOW.
  • Final results for the healthy subjects clinical trial are expected to be announced in December 2026.